(Total Views: 650)
Posted On: 04/11/2021 5:43:00 PM
Post# of 72440
Time Stamps for the Mason Scientific Video. (https://www.youtube.com/watch?v=kdFeqlmqzPQ)
Video Presentation by Aarthi Narayana Ph.D
Mason Science Series: Rising to the National and International COVID-19 Challenge
02:37 Introduction to; Aarthi Narayana, Ph.D. (anaraya1@gmu.edu) George Mason University
05:25 Aarthi Narayana presentation start
08:04 The RBL, Life before SARS-CoV-2
10:20 March 2020 Reactionary or Deliberate?
15:19 Pivot toward COVID-19 countermeasures
16:25 Therapeutics (including Synthetic peptides)
18:06 Innovation Pharmaceuticals – first mention
19:15 Repurposing FDA approved small molecules
20:32 Maraviroc (HIV therapeutic)
24:45 Discussion of PhysiCell modeling tools
26:03 Maraviroc in vivo
28:03 Maraviroc drug cocktails
30:10 Thank You- Leidos, Noble Life, VIIBRE
30:59 Blood Brain Barrier viral migration
32:48 Lung Organ-on-Chip intended testing ambitions
33:34 Dual function Antiviral synthetic peptides and peptidomimetics
Key to infection treatment is an ability to treat dual manifestation of illness
Progression of illness
35:50 synthetic peptides down selection
37:34 MOA disrupting viral integrity w/synthetic peptides
39:40 Lipid Membrane disruption
40:13 Innovation Pharmaceuticals (HDP/Defensin Mimetic) Brilacidin
Previously demonstrated robust antiviral and antibacterial activity
Demonstrated Inhibition of SARS-CoV-2 (peer review publication)
Variant Viral Inhibition and remdesvir combo
Studies expending to broad spectrum testing of Brilacidin
42:58 Heterotypic Biologics
Equine antibodies and Avian antibodies
45:40 Equine antibody evaluation results
46:40 Vaccine efforts
47:14 DNA origami NP
48:44 Lipid nano-particles challenge study
51:57 Chimeron Bio Dual Vaccine Design Strategy
53:30 Emergex Ligandome guided vaccine design
55:27 Mass spectra analysis results
56:46 Self derived peptide questions to answer
57:39 Acknowledging the work of the Center for Applied Proteomics and Molecular Medicine
58:50 General Thank You to Crew and Collaborators
01:01:40 Q and A
01:02:50 Periodic Outbreaks have occurred… have pathogen-agnostic modules ready to apply
01:04:15 Self-derived peptides potential to infer immunity?
01:05:00 Combination strategies are essential- therapeutics are necessary
01:07:35 NSP3 peptides – on the radar but yet to be explored
Video Presentation by Aarthi Narayana Ph.D
Mason Science Series: Rising to the National and International COVID-19 Challenge
02:37 Introduction to; Aarthi Narayana, Ph.D. (anaraya1@gmu.edu) George Mason University
05:25 Aarthi Narayana presentation start
08:04 The RBL, Life before SARS-CoV-2
10:20 March 2020 Reactionary or Deliberate?
15:19 Pivot toward COVID-19 countermeasures
16:25 Therapeutics (including Synthetic peptides)
18:06 Innovation Pharmaceuticals – first mention
19:15 Repurposing FDA approved small molecules
20:32 Maraviroc (HIV therapeutic)
24:45 Discussion of PhysiCell modeling tools
26:03 Maraviroc in vivo
28:03 Maraviroc drug cocktails
30:10 Thank You- Leidos, Noble Life, VIIBRE
30:59 Blood Brain Barrier viral migration
32:48 Lung Organ-on-Chip intended testing ambitions
33:34 Dual function Antiviral synthetic peptides and peptidomimetics
Key to infection treatment is an ability to treat dual manifestation of illness
Progression of illness
35:50 synthetic peptides down selection
37:34 MOA disrupting viral integrity w/synthetic peptides
39:40 Lipid Membrane disruption
40:13 Innovation Pharmaceuticals (HDP/Defensin Mimetic) Brilacidin
Previously demonstrated robust antiviral and antibacterial activity
Demonstrated Inhibition of SARS-CoV-2 (peer review publication)
Variant Viral Inhibition and remdesvir combo
Studies expending to broad spectrum testing of Brilacidin
42:58 Heterotypic Biologics
Equine antibodies and Avian antibodies
45:40 Equine antibody evaluation results
46:40 Vaccine efforts
47:14 DNA origami NP
48:44 Lipid nano-particles challenge study
51:57 Chimeron Bio Dual Vaccine Design Strategy
53:30 Emergex Ligandome guided vaccine design
55:27 Mass spectra analysis results
56:46 Self derived peptide questions to answer
57:39 Acknowledging the work of the Center for Applied Proteomics and Molecular Medicine
58:50 General Thank You to Crew and Collaborators
01:01:40 Q and A
01:02:50 Periodic Outbreaks have occurred… have pathogen-agnostic modules ready to apply
01:04:15 Self-derived peptides potential to infer immunity?
01:05:00 Combination strategies are essential- therapeutics are necessary
01:07:35 NSP3 peptides – on the radar but yet to be explored
(7)
(0)Scroll down for more posts ▼
